Effects of Trimetazidine on Oxidant-Antioxidant Balance and Angiogenesis; an in Vivo Experimental Study

Loading...
Publication Logo

Date

2025

Journal Title

Journal ISSN

Volume Title

Publisher

BMC

Open Access Color

GOLD

Green Open Access

Yes

OpenAIRE Downloads

OpenAIRE Views

Publicly Funded

No
Impulse
Average
Influence
Average
Popularity
Average

Research Projects

Journal Issue

Abstract

Background We evaluated the effects of trimetazidine (TMZ) on the oxidative-antioxidative balance and angiogenesis in an in vivo experimental model. This study aims to evaluate the effects of trimetazidine on angiogenesis through histological analysis and to assess its impact on oxidative-antioxidative balance through biochemical measurements. Methods In this study, Ross 308 breed chicken eggs (n = 40) were used, and embryos were divided into four distinct groups. On the eighth day of incubation, the vascular density of the embryos was examined. Following the assessment of vascular development, 4-5 mL of albumin was collected via syringe to measure oxidative stress markers. Each group consisted of 10 embryos, with a total of 40 embryos used in the study. The groups were organized as follows: Control Group (CG), Bevacizumab Group (BC), Trimetazidine 10(-)(4) Group, and Trimetazidine 10(-)(5) Group. Results When the total oxidative capacity (TOC) levels were compared among the groups, the bevacizumab group exhibited significantly higher values than the control group (p < 0.05). In oxidative stress index (OSI) measurements, the bevacizumab group also showed significantly higher values compared to the control group (p < 0.05). In contrast, when the total antioxidant capacity (TAC) levels were compared, both the Trimetazidine 10(-)(4) and Trimetazidine 10(-)(5) groups demonstrated significantly higher values than the control group (p < 0.05). Regarding angiogenesis scoring, the bevacizumab group exhibited a significant anti-angiogenic effect compared to the control group. However, no statistically significant difference was observed between the Trimetazidine 10(-)(4) and Trimetazidine 10(-)(5) groups and the control group (p > 0.05). Conclusion Trimetazidine demonstrated significant antioxidant activity in an in vivo Chorioallantoic Membrane (CAM) model at both 10(-)(4) M and 10(-)(5) M concentrations. However, no positive or negative effects on angiogenesis were detected. We believe that the real-time observation of angiogenesis in our study provided significant value to our research.

Description

Keywords

Trimetazidine, Angiogenesis, Coronary Artery Disease, Myocardial Ischemia, Myocardial ischemia, Research, Vasodilator Agents, Trimetazidine, Neovascularization, Physiologic, Angiogenesis Inhibitors, Chick Embryo, Oxidants, Coronary artery disease, Antioxidants, Bevacizumab, Oxidative Stress, RC666-701, Diseases of the circulatory (Cardiovascular) system, Animals, Angiogenesis, Microvascular Density

Fields of Science

Citation

WoS Q

Q2

Scopus Q

Q2
OpenCitations Logo
OpenCitations Citation Count
N/A

Source

BMC Cardiovascular Disorders

Volume

25

Issue

1

Start Page

End Page

PlumX Metrics
Citations

Scopus : 2

Captures

Mendeley Readers : 2

Google Scholar Logo
Google Scholar™
OpenAlex Logo
OpenAlex FWCI
3.5846016

Sustainable Development Goals